Boehringer Ingelheim announced today the launch of Vaxxilive Cocci 3, a poultry coccidiosis vaccine previously known as Hatchpak Cocci III.

Vaxxilive Cocci 3 is a tool for the prevention of coccidiosis and a biological alternative to in-feed anticoccidial drugs. The vaccine works to stimulate the bird’s natural immune response while minimizing tissue damage. In short: Vaxxilive Cocci 3 is tough on coccidiosis and gentle on birds.

The vaccine contains the same proven formula producers have come to rely on, including three genetically stable precocious strains of the important Eimeria species that affects broilers. With shortened life cycles, precocious strains can achieve immunity earlier than non-precocious strains.

Because the precocious strains have a faster turnover rate, Vaxxilive Cocci 3 triggers less oocyst production and less tissue damage. The vaccine ultimately achieves better immunity while preserving barrier integrity and producing minimal vaccine reactions. In addition, the vaccine can be used year-round, enabling better management of coccidiosis with less likelihood of developing chemical resistance than protocols that rotate between vaccination, chemical treatment and feed additives.

Boehringer has also used this launch as an opportunity for process innovation, drastically improving procedures to enable more consistent, quality manufacturing. 

“As with any vaccination, choosing a product is only half the battle,” said Rick Phillips, DVM, director of Key Account Veterinarians for Boehringer Ingelheim Poultry. “Our experienced and knowledgeable field team provides industry-leading support to producers, regularly visiting them to review vaccination protocols, and create and maintain comprehensive poultry health programs.”

Vaxxilive Cocci 3 is now widely available.